Inventiva SA
PAR:IVA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.45
4.24
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Inventiva SA
Inventiva SA
Accounts Receivables
Inventiva SA
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Inventiva SA
PAR:IVA
|
Accounts Receivables
€809k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Accounts Receivables
€30.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Nanobiotix SA
PAR:NANO
|
Accounts Receivables
€3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
117%
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Accounts Receivables
€61.5m
|
CAGR 3-Years
380%
|
CAGR 5-Years
83%
|
CAGR 10-Years
90%
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Accounts Receivables
€27m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
11%
|
CAGR 10-Years
17%
|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Accounts Receivables
€5m
|
CAGR 3-Years
89%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
Inventiva SA
Glance View
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
See Also
What is Inventiva SA's Accounts Receivables?
Accounts Receivables
809k
EUR
Based on the financial report for Jun 30, 2024, Inventiva SA's Accounts Receivables amounts to 809k EUR.
What is Inventiva SA's Accounts Receivables growth rate?
Accounts Receivables CAGR 1Y
-63%
Over the last year, the Accounts Receivables growth was -63%.
You don't have any saved screeners yet
